EXASOL AG

  • WKN: A0LR9G
  • ISIN: DE000A0LR9G9
  • Land: Deutschland

Nachricht vom 25.11.2021 | 09:20

DGAP-DD: EXASOL AG english


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
25.11.2021 / 09:19
The issuer is solely responsible for the content of this announcement.

1. Details of the person discharging managerial responsibilities / person closely associated

a) Name
Title:
First name: Aaron
Last name(s): Auld

2. Reason for the notification

a) Position / status
Position: Member of the managing body

b) Initial notification

3. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name
EXASOL AG

b) LEI
529900ZPF6KHG6O3GY79 

4. Details of the transaction(s)

a) Description of the financial instrument, type of instrument, identification code
Type: Share
ISIN: DE000A0LR9G9

b) Nature of the transaction
Acquisition

c) Price(s) and volume(s)
Price(s) Volume(s)
6.67 EUR 2401.20 EUR
6.675 EUR 2382.98 EUR
6.70 EUR 402.00 EUR
6.725 EUR 4862.18 EUR

d) Aggregated information
Price Aggregated volume
6.6989 EUR 10048.3600 EUR

e) Date of the transaction
2021-11-23; UTC+1

f) Place of the transaction
Name: XETRA
MIC: XETS



25.11.2021 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Infineon Technologies AG: Aufsichtsrat beruft Jochen Hanebeck zum Nachfolger von Dr. Reinhard Ploss als Vorstandsvorsitzenden von Infineon

25. November 2021, 17:45

Aktuelle Research-Studie

3U HOLDING AG

Original-Research: 3U HOLDING AG (von GSC Research GmbH): Halten

26. November 2021